Wednesday, December 23, 2020

MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Closes $100M Underwritten Public Offering

 VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the closing of its $100 million underwritten public offering. The offering consisted of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share, and 2,000,000 shares of its Series D convertible preferred stock at a public offering price of $21.16 per share. All of the securities in the offering were sold by VistaGen. Acuta Capital, New Enterprise Associates (“NEA”), OrbiMed and Venrock Healthcare Capital Partners, among others, participated in the offering as lead investors. VistaGen intends to use the net proceeds for research, development and manufacturing and regulatory expenses associated with continuing development of PH94B, PH10, AV-101, and potential drug candidates to expand its CNS pipeline and for other working capital and general corporate purposes. Jefferies LLC and William Blair & Company, L.L.C. acted as joint book-running managers for the offering and Maxim Group LLC acted as a financial advisor.

To view the full press release, visit https://ibn.fm/S5iNS

About VistaGen Therapeutics Inc.

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on TwitterLinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN  

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html